Lifestyle, Not Race, Plays Major Role in Lung Cancer Survival

Publication
Article
OncologyONCOLOGY Vol 9 No 6
Volume 9
Issue 6

Race does not play a stastically significant role in lung cancer patients'survival, a recent analysis shows. Instead, cigarette use, stage of disease, and other factors appear to be reasons more African-Americans die of lung cancer than their Caucasian

Race does not play a stastically significant role in lung cancerpatients'survival, a recent analysis shows. Instead, cigaretteuse, stage of disease, and other factors appear to be reasonsmore African-Americans die of lung cancer than their Caucasiancounterparts, the analysis indicates.

The analysis reviewed 1,565 patients with non-small-cell lungcancer who were treated on cancer research studies conducted bythe Radiation Therapy Oncology Group (RTOG).

"We looked at possible factors that could influence survival,"says Dr. Jim Cox, Professor of Radiotherapy at the Universityof Texas, M. D. Anderson Cancer Center in Houston. "We foundthat age, sex, weight loss, stage of disease, and the amount ofsymptoms patients had when they were diagnosed with lung canceraffected survival. For example, older patients with later stagedisease and more symptoms tended to have a shorter survival time,"says Dr. Cox, an author of the study. Race did not make a statisticallysignificant difference, he says.

Smoking rates among African-American adults are higher than thosefor Caucasians. Black smokers are more likely to smoke highertar and nicotine brands than are white smokers, and smoking highertar brands is associated with higher lung cancer incidence andmortality rates, according to the US Department of Health andHuman Services.

"I strongly believe we can make a positive difference inshows.Instead, cigarette use, stage of disease, and other factors appearto be reasons more African-Americans die of lung cancer than theirCaucasian counterparts, the analysis indicates.

The analysis reviewed 1,565 patients with non-small-cell lungcancer who were treated on cancer research studies conducted bythe Radiation Therapy Oncology Group (RTOG).

"We looked at possible factors that could influence survival,"says Dr. Jim Cox, Professor of Radiotherapy at the Universityof Texas, M. D. Anderson Cancer Center in Houston. "We foundthat age, sex, weight loss, stage of disease, and the amount ofsymptoms patients had when they were diagnosed with lung canceraffected survival. For example, older patients with later stagedisease and more symptoms tended to have a shorter survival time,"says Dr. Cox, an author of the study. Race did not make a statisticallysignificant difference, he says.

Smoking rates among African-American adults are higher than thosefor Caucasians. Black smokers are more likely to smoke highertar and nicotine brands than are white smokers, and smoking highertar brands is associated with higher lung cancer incidence andmortality rates, according to the US Department of Health andHuman Services.

"I strongly believe we can make a positive difference inthe survival rates of lung cancer patients," says Dr. Cox."We know smoking is deadly. People need to take responsibility.They should quit smoking whether they have lung cancer now ornot. If they do have lung cancer they also need to seek the bestquality of care-such as the kind of care that is found in clinicaltrials," he says.

Recent Videos
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content